Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Share-based Compensation (IS) (2022 - 2024)

Indivior Pharmaceuticals has reported Share-based Compensation (IS) over the past 3 years, most recently at $6.0 million for Q4 2024.

  • For Q4 2024, Share-based Compensation (IS) changed 0.0% year-over-year to $6.0 million; the TTM value through Dec 2024 reached $24.0 million, up 9.09%, while the annual FY2024 figure was $24.0 million, 9.09% up from the prior year.
  • Share-based Compensation (IS) for Q4 2024 was $6.0 million at Indivior Pharmaceuticals, down from $7.0 million in the prior quarter.
  • Over five years, Share-based Compensation (IS) peaked at $7.0 million in Q3 2024 and troughed at $4.0 million in Q4 2022.
  • A 3-year average of $5.5 million and a median of $5.5 million in 2022 define the central range for Share-based Compensation (IS).
  • On a YoY basis, Share-based Compensation (IS) climbed as much as 50.0% in 2023 and fell as far as 0.0% in 2023.
  • Year by year, Share-based Compensation (IS) stood at $4.0 million in 2022, then skyrocketed by 50.0% to $6.0 million in 2023, then changed by 0.0% to $6.0 million in 2024.
  • Business Quant data shows Share-based Compensation (IS) for INDV at $6.0 million in Q4 2024, $7.0 million in Q3 2024, and $6.0 million in Q2 2024.